Effect of inactivated Bifidobacterium longum intake on obese diabetes model mice (TSOD)

Food Res Int. 2020 Mar:129:108792. doi: 10.1016/j.foodres.2019.108792. Epub 2019 Nov 21.

Abstract

Obesity and diabetes have been increasing at an alarming rate worldwide. Studies have shown the futility of chemical drugs in the treatment of obesity and diabetes. Bifidobacterium longum (BL), a common member of the gut microbiota throughout the human lifespan, has been widely reported to play a role in host health and disease. Here, we evaluated the effects of inactivated cells of BL (IBL) on obesity and blood glucose levels in TSOD mice by administering IBL orally for 5 weeks. The treated mice showed a significant decrease of body weight gain, adipose tissue mass and blood glucose levels, as well as a significant reduction in blood glucose during an oral glucose tolerance test. The treatment also resulted in reduced levels of cholesterol, triglycerides, and NEFA. Moreover, serum and urine analysis showed low creatinine levels in IBL-treated mice. These data demonstrate that IBL may have the potential to prevent obesity and diabetes.

Keywords: Bifidobacterium longum; Glucose level; Obesity; Paraprobiotics; TSOD mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / metabolism
  • Animals
  • Bifidobacterium longum / metabolism*
  • Blood Glucose / metabolism
  • Cholesterol / blood
  • Creatinine / blood
  • Creatinine / urine
  • Diabetes Mellitus / prevention & control
  • Diabetes Mellitus, Experimental*
  • Dyslipidemias / blood
  • Dyslipidemias / microbiology
  • Fatty Acids, Nonesterified / blood
  • Gastrointestinal Microbiome
  • Glucose Tolerance Test
  • Male
  • Mice
  • Mice, Obese*
  • Obesity / prevention & control
  • Triglycerides / blood
  • Weight Gain

Substances

  • Blood Glucose
  • Fatty Acids, Nonesterified
  • Triglycerides
  • Cholesterol
  • Creatinine